Navigation Links
Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
Date:6/20/2008

d by the reduction of NT-proBNP plasma concentration in the bosentan-treated group compared to the increase in the placebo-treated patients. It is generally considered that a decrease in plasma concentration of NT-proBNP following targeted PAH therapy is a predictive factor for patient outcome.

An open-label extension of EARLY is ongoing to establish the impact of early intervention on long-term patient outcome.

Notes to editor

About Pulmonary Arterial Hypertension (PAH)

PAH is a syndrome characterized by a progressive increase in pulmonary vascular resistance (PVR) leading to right ventricular failure and premature death.(4) If untreated, PAH carries a very poor prognosis with a median survival of 2.8 years after diagnosis.(5)

There are four WHO functional classes for PAH with class I being the least severe and class IV being the most advanced. These reflect the impact on a patient's life in terms of symptoms and physical activity. Class II patients are defined as patients with pulmonary hypertension resulting in mild limitation of physical activity, they are comfortable at rest and ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope.(6)

The pathogenesis of PAH involves the increased production of vasoactive compounds, such as endothelin. Endothelin is produced by the endothelial cells and is essential for maintenance of normal vascular tone and function. Tracleer(R) was the first in a new class of treatments for PAH known as endothelin receptor antagonists. Tracleer(R) is a dual antagonist as it blocks both ETA and ETB receptors preventing the deleterious effects of endothelin.

Online information on PAH is available at http://www.pah-info.com. PAH-info.com is part of an international PAH awareness campaign supported by Actelion Pharmaceuticals and has been created to provide information to healthcare professionals and patients. '/>"/>

SOURCE Actelion Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
2. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
3. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
4. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
5. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
8. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
9. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
10. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
11. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  Columbia Laboratories, Inc. (Nasdaq: ... today announced financial results for the three and ... "Second quarter results benefited from the contribution ... diversified revenue stream partially offset an anticipated and ... during a routine license renewal in one high-volume, ...
(Date:7/31/2014)... 31, 2014 Marken announced today the expansion ... meet the clinical trial logistics growth in Central and ... facility will continue to serve as a regional center ... from the region, and will provide additional storage capacity. ... combine its office and warehouse into a single facility, ...
(Date:7/31/2014)... , July 31, 2014 ... and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, Long-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... Report. Diabetes, growing at an exponential rate ... has emerged as a major cause of death of ...
Breaking Medicine Technology:Columbia Laboratories Reports Second Quarter 2014 Financial Results 2Columbia Laboratories Reports Second Quarter 2014 Financial Results 3Columbia Laboratories Reports Second Quarter 2014 Financial Results 4Columbia Laboratories Reports Second Quarter 2014 Financial Results 5Columbia Laboratories Reports Second Quarter 2014 Financial Results 6Columbia Laboratories Reports Second Quarter 2014 Financial Results 7Columbia Laboratories Reports Second Quarter 2014 Financial Results 8Columbia Laboratories Reports Second Quarter 2014 Financial Results 9Columbia Laboratories Reports Second Quarter 2014 Financial Results 10Columbia Laboratories Reports Second Quarter 2014 Financial Results 11Columbia Laboratories Reports Second Quarter 2014 Financial Results 12Marken Expands Miami Regional Logistics Center 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 2The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 3The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 4The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 5The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 6The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 7The Global and China Insulin Market is Expected to Grow at a CAGR of 6.1% From 2013 to 2019 to Reach USD 32.24 Billion in 2019 8
... Electronics, Inc. (NYSE: BHE ), a leading ... it helped commercialize and currently manufactures has won the ... for best new science and medical diagnostic product. ... 2011 Medical Design Excellence Award in the In Vitro ...
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... and CEO will deliver a corporate presentation on Thursday, ... The presentation will take place as part of the ...
Cached Medicine Technology:Benchmark Electronics Recognized as Supplier for 2011 Design Medical Excellence Award Winner 2
(Date:7/31/2014)... bill introduced in Congress with bipartisan support would allow ... Michigan research, which could improve the health of patients ... the medicines and tests they need most. , The ... and Earl Blumenauer, grew out of a decade of ... Institute for Healthcare Policy and Innovation. It would allow ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of cancer ... Heat-Shock Factor 1 (HSF1) can also turn neighboring ... malignant progression and metastasis. , The finding, reported ... journal Cell , lends new insights into ... prognosis, and management of cancer patients. , ...
(Date:7/31/2014)... 31, 2014 The North America Phytochemicals & ... plant extracts market in North America with analysis and forecast ... around $576.3 million in 2012 to $930.1 million by 2018, ... Browse through the TOC of the North America phytochemicals & ... in-depth analysis provided. It also provides a glimpse of the ...
(Date:7/31/2014)... York, NY (PRWEB) July 31, 2014 ... publication dedicated to delivering cutting-edge information focused ... and therapeutics, recently launched its newly designed ... website optimizes navigation by providing visitors specialized ... analytical and strategic business areas. As the ...
Breaking Medicine News(10 mins):Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:BioProcess International Launches New Website 2
... and observational studies show an increased risk for cancer ... problem may be worse than currently known. ... going to see the current disparity in knowledge and ... director of the Institute for Health Promotion Research at ...
... Researchers at the University of Alabama at Birmingham ... four biomarkers that will help predict which patients are ... are not. The findings also shed light on the ... African-Americans, compared with Caucasians, the researchers said. In ...
... John Theurer Cancer Center at Hackensack University Medical Center ... patients on Friday, April 23 and Saturday, April 24. ... Management of Hematological Malignancies", is part of John Theurer ... well as patients with an update on the newest ...
... heart problems that stems from a genetic defect in the ... protein,s function can lead to cardiac arrest, which is exactly ... investigation at Sahlgrenska University Hospital at the University of Gothenburg, ... today in the revered New England Journal of Medicine ...
... ... release of their new title in the Tarascon Pocketbook series, Tarascon Global Health Pocketbook, ... portable guide provides regional and issue-based information on international medicine throughout the world. ... Sudbury, MA (Vocus) ...
... Study found infection rates highest among black children in ... -- Treatment-resistant ringworm is common among urban elementary school ... in kindergarten through Grade 5 at 44 schools across ... 6.6 percent of them were infected with the fungus ...
Cached Medicine News:Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 2Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 3Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 4Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 5Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 6Health News:Cancer health disparities research highlighted at AACR 101st Annual Meeting 2010 7Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 2Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 3Health News:John Theurer Cancer Center hosts hematologic malignancies program for physicians and patients 4Health News:New explanation for cardiac arrest 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 2Health News:Tarascon Announces New Title In Their Pocketbook Series: Global Health 3Health News:Resistant Ringworm Common in Urban Elementary Schools 2
... Implants are comprised only of synthetic, medical ... designed to support soft tissue ingrowth. Ocu-pore ... sizes. The material is manufactured using a ... produce a highly porous, fully interconnected, biocompatible ...
Straight iris forceps. Insulated....
Bayonet forceps....
Semkin forceps with stops. Insulated....
Medicine Products: